Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

SGLT2 Inhibition for Cardiovascular Endpoint Reduction in Hypertension

NCT06804161 is registered in ClinicalTrials.gov with Prof. Dr. med. Ingo Eitel as lead sponsor.

NCT NCT06804161
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06804161 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
SGLT2 Inhibition for Cardiovascular Endpoint Reduction in Hypertension
Lead sponsor
Prof. Dr. med. Ingo Eitel
Phase
Phase 3
Overall status
Recruiting
Start date
December 10, 2025
Completion date
May 30, 2032
Enrollment
3,000 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

atrial hypertension